UGRO CAPITAL LIMITED PUBLIC ISSUE OF SECURED, RATED, LISTED, REDEEMABLE, NON-CONVERTIBLE DEBENTURES (SECURED NCDS) OPENS TODAY EFFECTIVE ANNUALIZED YIELD UP TO 11.01% PER ANNUM*

▴ UGRO Capital Limited
The NCDs are proposed to be listed on BSE and NSE (collectively, “Stock Exchanges”). Allotments, in consultation with the National Stock Exchange of India Limited (the “Designated Stock Exchange”), shall be made on the basis of the date of upload of the application on the electronic book of the Stock Exchanges in accordance with the SEBI Master Circular. However, on the date of oversubscription and thereafter, the allotment shall be made to the applicants on a proportionate basis.
 
  • Secured NCDs of face value (“Face Value”) of Rs. 1,000 each.
  • The Issue is for an amount of ? 10,000 lakh (“Base Issue Size”) with an option to retain oversubscription up to     ? 10,000 lakh (“Green Shoe Option”) aggregating up to ? 20,000 lakh.
  • Rated as “IND A+/Stable” by India Ratings and Research Private Limited.
  • Effective annualized yield up to 11.01% p.a*.        
  • The Issue opens on Thursday, April 3, 2025 and closes on Monday, April 21, 2025 with an option of early closure subject to compliance with Regulation 33A of the SEBI NCS Regulations**.
 
Hyderabad, April 3, 2025: UGRO Capital Limited, an NBFC focused on MSME lending, today announced the issue of secured, rated, listed, redeemable, non-convertible debentures of the face value of ? 1,000 each. The Issue has a base issue size of ? 10,000 lakhs with an option to retain oversubscription up to ? 10,000 lakh, aggregating up to ? 20,000 lakh. The Issue opens on Thursday, April 3, 2025 and closes on Monday, April 21, 2025 with an option of early closure subject to compliance with Regulation 33A of the SEBI NCS Regulations.
The NCDs are proposed to be listed on the Stock Exchanges and NSE is the Designated Stock Exchange for the Issue. The NCDs have been rated “IND A+/Stable” by India Ratings and Research Private Limited. Securities with this rating are considered to have adequate degree of safety regarding timely servicing of financial obligations.
Tipsons Consultancy Services Private Limited is the sole lead manager to the issue and MUFG Intime India Private Limited (formerly known as Link Intime India Private Limited) is the Registrar to the Issue and MITCON Credentia Trusteeship Services Limited is the debenture trustee to the Issue.
This issue has tenor of 18 months, 24 months, 30 months, and 42 months for secured NCDs. Effective yield (% per annum) for NCD holders in all Categories ranges from 10.47% to 11.01%. Redemption Amount (? / NCD) on maturity for NCD holders in all Categories range is ? 1000.
At least 75% of the Net proceeds of the Issue shall be utilized for the purpose of onward lending and financing business of the company in ordinary course of business (including for repayment / refinance of existing debts of the Company) and Not exceeding 25% shall be used for general corporate purposes.
As on December 31, 2024 UGRO Capital’s CRAR, in accordance with the Limited Reviewed Financial Results was at 21.52%. Its AUM has grown from ?2,96,890.60 lakh as of March 31, 2022, to ?9,04,705.74 lakh as of March 31, 2024. As of December 31, 2024, the Company was operating from 23 prime branches and 201 Emerging Market branches with an AUM of ? 11,06,656.73 lakh and catering more than 1,35,000 lakh customers. Across the offered products, as on December 31, 2024, the average ticket size stood at ? 11.37 lakh and the portfolio yield stood at 16.65%.
The specified terms of the NCDs Issue are set out below:
Series
I
II
III
IV
V*
Frequency of Interest Payment
Monthly
Annually
Monthly
Monthly
Monthly
Minimum Application
? 10,000 (10 NCDs) across all Series
Face Value/ Issue Price of NCDs (?/ NCD)
?1000 (1 NCD)
In Multiples of thereafter (?)
? 1000 (1 NCD)
Tenor
18 Months
18 Months
24 Months
30 Months
42 Months
Coupon (% per annum) for NCD Holders in Category I, II, III & IV
10.00%
10.39%
10.15%
10.25%
10.50%
Effective Yield (per annum) for NCD Holders in Category I, II, III & IV
10.47%
10.47%
10.64%
10.75%
11.01%
Mode of Interest Payment
Through various modes available
Amount (? / NCD) on Maturity for NCD Holders in Category I, II, III & IV
?1000 (1 NCD)
Maturity / Redemption Date (Months from the Deemed Date of Allotment)
Date occurring on expiry of 18 (Eighteen) months from the Deemed Date of Allotment
Date occurring on expiry of 18 (Eighteen) months from the Deemed Date of Allotment
Date occurring on expiry of 24 (Twenty Four) months from the Deemed Date of Allotment
Date occurring on expiry of 30 (Thirty) months from the Deemed Date of Allotment
Date occurring on expiry of 42 (Forty Two) months from the Deemed Date of Allotment
Put and Call Option
NA
NA
NA
NA
NA
* Our Company shall allocate and allot Series V NCDs wherein the Applicants have not indicated the choice of the relevant NCD Series.
Tags : #

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-



Trending Now

AI for Rare Diseases: Can Algorithms Help Doctors Solve Diagnostic Mysteries?September 09, 2026
AI-Powered Emergency Rooms: The Next Transformation in Hospital CareSeptember 09, 2026
Happiest Health Expands Project Khushi with Bengaluru City Police, to Reach 600 Personnel Over Three YearsSeptember 08, 2026
Doctors at Nanavati Max Hospital Successfully Replants Amputated Thumb of a 69-Year-Old Mumbai Taxi Driver after Eight-Hour MicrosurgerySeptember 08, 2026
MGM Healthcare Performs Open Surgical Chest Contour on a 44-year-Old Man with Liver FailureSeptember 08, 2026
SIMS Hospital Performs Asia’s First New-Generation Bone-Sparing Hip Procedure on International PatientsSeptember 08, 2026
Senior Care Experts Call for Long-Term Care to Be Recognised as a Distinct Insurable RiskSeptember 08, 2026
The Rise of Lifestyle-Related Musculoskeletal Problems Among Young IndiansSeptember 08, 2026
Healthy Protein Choices for Indian Families: Vegetarian and Non-Vegetarian Options ExplainedSeptember 08, 2026
Understanding Fatigue: Common Causes, Helpful Questions, and When Evaluation MattersSeptember 08, 2026
AI Medical Scribes in India: Can They Reduce Doctors' Documentation Burden?September 08, 2026
Can AI Predict Patient Deterioration Before Doctors Notice the Warning Signs?September 08, 2026
Understanding Food Allergies in Children: Symptoms, Testing, and Safer Family MealsSeptember 07, 2026
Why Regular Walking Matters: Building a Safe Daily Activity Routine for Indian AdultsSeptember 07, 2026
The Future of Cashless Hospitalisation in India: Policy, Technology, and the Road to Universal AccessSeptember 07, 2026
Health Claims Exchanges: Could Technology Finally Fix Insurance Processing in India?September 07, 2026
Healthy Cooking Oils in India: Comparing Fat Types for Everyday Family MealsSeptember 05, 2026
Understanding Migraine Aura: Visual Symptoms, Triggers, and When to Seek Medical AdviceSeptember 05, 2026
Pharmacogenomics: Could Genetic Testing Help Doctors Choose the Right Drug?September 05, 2026
Precision Medicine in India: Is Personalized Treatment Finally Becoming Practical?September 05, 2026